Recent advances in the development of nanomaterials for DC-based immunotherapy

作     者：Ligeng Xu Jian Xiang Rui Peng Zhuang Liu 

作者机构：Institute of Functional Nano and Soft Materials (FUNSOM)Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices Soochow University 

出 版 物：《Science Bulletin》 (科学通报（英文版）)

年 卷 期：2016年第61卷第7期

页      面：514-523页

核心收录：

学科分类：07[理学] 070205[理学-凝聚态物理] 08[工学] 080501[工学-材料物理与化学] 0805[工学-材料科学与工程（可授工学、理学学位）] 0702[理学-物理学] 

基　　金：supported by the National Basic Research Program of China (2012CB932601, 2011CB911000) the National Natural Science Foundation of China (51222203, 31300824, 51302180) the Natural Science Foundation of Jiangsu Province (BK20130005) China Postdoctoral Science Foundation (2013M530267) 

主　　题：Dendritic cells Immunotherapy Cancer vaccine Tracking Nanomaterials 

摘      要：As professional antigen presenting cells, dendritic cells(DCs) greatly determine the quality of the innate and adaptive immunities. Therefore, DC-based immunotherapy has been one of the hotspots in cancer immunotherapy in recent years. Although this unique therapeutic strategy has been approved by U.S. Food and Drug Administration for prostate cancer treatment, the efficacy of DC-based immunotherapy remains to be further improved. Moreover, it is still not completely clear about the immunological basis of DCs, which is another hurdle for the progress of DC-based immunotherapy. Due to their unique physicochemical properties, nanomaterials have shown potentials in addressing these above mentioned problems and have provided important guidelines for optimizing DC-based immunotherapy. However, it is still at the starting stage for this emerging field and there are many critical questions in the rational design of this therapeutic strategy to be answered. Therefore, it is greatly necessary to review and analyze recent progresses in this field. In this review, we mainly focus on the development of various types nanoparticles for DC-based immunotherapy. The existed challenges in this field are also discussed.